InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,609.31
(
-0.30%
)
US TECH 100
18,818.80
(
-1.02%
)
Dow Jones
41,521.34
(
0.31%
)
Brent Oil
72.39
(
1.40%
)
Bitcoin
57,617.63
(
-2.63%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rocky301

Send PM Follow Ignore
Followers 110
Posts 6480
Boards Moderated 0
Alias Born 05/01/2003

rocky301

Re: petekoz1 post# 21476

Wednesday, 12/30/2009 9:07:20 AM

Wednesday, December 30, 2009 9:07:20 AM

Post# of 92948
pete,

ACTC Pr'd on Nov.19th they filed the IND. This article snippet shows it was filed Nov. 18th, on a Wednesday. If they sent the 9 volumes of safety data via snail mail then maybe the 23rd is when it was received..

"Lanza said ACT decided to target Stargardt’s macular dystrophy first because it has been designated an “orphan disease” and could benefit from a faster regulatory review. The FDA has 30 days to respond to the company’s filing, made Wednesday, and the clinical trial could begin early next year."
http://latimesblogs.latimes.com/booster_shots/2009/11/human-embyronic-stem-cells-stargardts-macular-dystrophy.html

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up